Faron Pharmaceuticals
2.035
EUR
-2.4 %
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreCoverage

Analyst
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
Annual report '24
General meeting '25
Interim report Q2'25
Risk
Change of Broker
Holding(s) in Company
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
As expected, Faron raised funding through a directed issue
Results of the Significantly Oversubscribed Placing
Proposed Issue and Placing
Faron Phase I/II BEXMAB trial patient enrollment completed; topline readout postponed to April
Final Patient Identified for the BEXMAB Study

Drug development investment: Value creation through M&As and licensing agreements
Faron Pharmaceuticals Oy: Faron's Financial Calendar for 2025
Faron: Towards final read-out in March

Faron Pharmaceuticals, BEXMAB Study Update
Faron Pharmaceuticals Oy: Faron presents BEXMAB data at ASH Annual Meeting

Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024

Regulation of drug development
Life Science Night available on inderesTV
Progress for Faron in the UK

Life Science Companies as Investments | Life Science Night Dec. 2, 2024
